Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-11-23

FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Nuplazid (pimavanserin tartrate) from Acadia Pharmaceuticals, resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nuplazid (Pimavanserin)

Snippet

SUPPL AP for NUPLAZID (PIMAVANSERIN TARTRATE)